根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价，包括：(a)5000万美元的首付 款，(b)500万美元的近期付款，及(c)向公司发行及配发于Solstice Oncology的超过5000万美元的股权。 此外，公司亦有资格视乎若干未来事件的达成情况，获得最高约11亿美元的额外开发、监管及商业里程 碑付款，以及基于HBM4003在大中华区以外地区净销售额的分级特许权使用费。 格隆汇2月23日丨和铂医药-B(02142.HK)发布公告，公司已与Solstice Oncology(一家由多个大型风险投 资机构创立的临床阶段生物技术公司)订立独家授权协议及股权合作协议("该等协议")，据此，公司同意 向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产 HBM4003。 公司将依托此契机，通过创新合作模式进一步加强全球合作网络，实现公司技术平台科学与商业价值的 最大化。订立该等协议可通过与经验丰富的投资机构共建专注于HBM4003开发的全球生物技术公司， 加速HBM4003在大中华区以外地区的全球开发和商业化。此合作模式不仅能实现长期价值创造，亦使 ...

公司将依托此契机，通过创新合作模式进一步加强全球合作网络，实现公司技术平台科学与商业价值的 最大化。订立该等协议可通过与经验丰富的投资机构共建专注于HBM4003开发的全球生物技术公司， 加速HBM4003在大中华区以外地区的全球开发和商业化。此合作模式不仅能实现长期价值创造，亦使 公司能够深度参与并推动该资产的全球开发进程。 智通财经APP讯，和铂医药-B(02142)发布公告，公司已与Solstice Oncology(一家由多个大型风险投资机 构创立的临床阶段生物技术公司)订立独家授权协议及股权合作协议(该等协议)，据此，公司同意向 Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。 根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价，包括：5000万美元的首付款， 500万美元的近期付款，及向公司发行及配发于Solstice Oncology的超过5000万美元的股权。此外，公司 亦有资格视乎若干未来事件的达成情况，获得最高约11亿美元的额外开发、监管及商业里程碑付款，以 及基于HBM4003在大中华区以外地区净销售额的分 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 與SOLSTICE ONCOLOGY 就HBM4003訂立授權協議及股權合作協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 本公司董事會（「董事會」）欣然宣佈，本公司已與Solstice Oncology（一家由多個大 型風險投資機構創立的臨床階段生物技術公司）訂立獨家授權協議及股權合作協 議（「該等協議」），據此，本公司同意向Solstice Oncology授予獨家授權，以在大 中華區以外地區開發及商業化其臨床階段組合資產HBM4003。 根據該等協議的條款，本公司有資格獲得價值超過105百萬美元的前期對價，包 括：(a) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 澄清公告 茲提述和鉑醫藥控股有限公司（「本公司」）日期為2024年1月12日、2024年4月3 日、2025年4月29日、2025年7月2日、2025年9月3日、2025年9月10日及2026年 1月1日有關授出購股權的公告（各稱為「該公告」，統稱「該等公告」）、本公司截 至2024年6月30日止六個月的中期報告（「2024年中期報告」）及截至2025年6月30 日止六個月的中期報告（「2025年中期報告」，統稱「中期報告」），以及本公司截至 2022年12月31日止年度的年度報告（「2022年年度報告」）、截至2023年12月31日 止年度的年度報告（「2023年年度報告」）及截至2024年12月31日止年度的年度報 告（「2024年年度報告」，統稱「年度報告」）。除另有說明外， ...

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Summary of the Conference Call for Heptares Therapeutics Company Overview - Heptares Therapeutics is a biotechnology company focused on innovative drug development, particularly in the fields of immunology and oncology. The company has established a strong position in the Chinese market for innovative drug business development (BD) transactions, contributing significantly to the industry. Key Points Industry Insights - The total value of BD transactions in China's innovative drug sector is projected to reach $135 billion in 2025, with Heptares contributing approximately $7 billion [2][10] - 2025 is noted as a year with a high concentration of BD events, leading to explosive growth in the industry, driven by major companies like Heptares and Heng Rui [3] Financial Performance - Heptares is expected to achieve a revenue of approximately $170 million in 2025, with a net profit close to $100 million [4][16] - For 2026, revenue is projected to grow to about $300 million, corresponding to a profit of approximately $160 million to $170 million, representing a year-on-year growth of over 60% [4][16] - As of mid-2025, Heptares held $320 million in cash, indicating a strong financial position supported by previous BD transactions and investments from major stakeholders like AstraZeneca [7] Core Technologies and Platforms - Heptares has developed several key technology platforms, including the Harbor Mice platform for fully human antibodies and the HBIAS platform for TCE bispecific antibodies [8][9] - The company’s platforms enhance molecular adaptability and research efficiency, allowing for the development of differentiated pipelines, including CTLA-4 antibody 4,003 and TSLP monoclonal and bispecific antibodies [2][5] Clinical Development Highlights - In the immunology field, the TSLP long-acting fully human antibody 9,378 has a half-life two to three times longer than currently marketed TSLP antibodies and can be administered subcutaneously [12] - In oncology, the CTLA-4 antibody 4,003 has shown promising Phase II clinical data in microsatellite instability tumors, positioning it as a potential best-in-class product [12][14] Strategic Partnerships - Heptares has formed significant partnerships, including a major collaboration with AstraZeneca involving a $175 million upfront payment and milestone payments totaling $4.4 billion [2][10] - The company has also established partnerships with other multinational corporations such as Pfizer and BMS, enhancing its market presence and collaborative potential [10] Future Outlook - The company anticipates stable performance growth in 2026, with a focus on clinical data development rather than solely event-driven factors [3][17] - Heptares aims to complete 1-2 new transactions annually, contributing to ongoing revenue growth and cash flow generation [16] - The overall industry trend is shifting towards performance growth and clinical advancement, with expectations for strong financial results in upcoming reports [17] Valuation and Market Position - Heptares is currently valued at approximately HKD 20 billion, with a projected price-to-earnings ratio of 15x for 2025, 8x for 2026, and 10x for 2027 [5][16] - The company is viewed as a quality investment opportunity due to its low valuation and strong growth potential in the innovative drug sector [17]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 呈交日期: 2026年2月6日 I. 法定/註冊股本變動 FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 868,681,522 | 25,437,000 | | 894,118,522 | | 增加 / 減少 (-) | | | 910,000 | 500,000 | | | | 本月底結存 | | | 869,591,522 | 25,937,000 | | 895, ...

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), anticipates significant profit growth for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Forecast - The expected adjusted profit for the company ranges from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1] - The profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1] Group 2: Revenue Drivers - The growth in recurring revenue is driven by ongoing research collaborations with partners such as AstraZeneca and Bristol-Myers Squibb [1] - The global partnership network is expanding, leading to revenue from licensing and collaborations, including partnerships with Otsuka Pharmaceutical and Windward Bio [1] - Rapid growth in the business of Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing with Pfizer [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has announced a significant increase in expected profits for the fiscal year ending December 31, 2025, leading to a stock price increase of over 3% following the announcement [1] Financial Performance - The expected profit for the fiscal year ending December 31, 2025, is projected to be between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an expected profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] - The adjusted total profit is anticipated to be between $91 million (approximately HKD 708 million) and $98 million (approximately HKD 763 million) [1] Revenue Drivers - The increase in expected profits is primarily attributed to the continuous growth of the company's recurring revenue, including research collaborations with AstraZeneca and Bristol-Myers Squibb [1] - The global partnership network is expanding rapidly, with revenue from innovative product licensing and collaborations contributing to the company's recurring income, such as licensing agreements with Otsuka Pharmaceutical and Windward Bio [1] - The rapid growth of the business at Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as research and technology licensing agreements with Pfizer, is also a significant factor [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), anticipates a significant increase in profits for the fiscal year ending December 31, 2025, projecting earnings between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an estimated profit of about $2.7 million for the fiscal year ending December 31, 2024 [1]. Financial Projections - The adjusted total profit is expected to range from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1]. - The profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1]. Revenue Drivers - Revenue growth is supported by research collaborations with AstraZeneca and Bristol-Myers Squibb [1]. - The accelerated expansion of the global partnership network has also contributed to revenue growth, including licensing collaborations with Otsuka Pharmaceutical and Windward Bio [1]. - Rapid growth in the business of Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from research and technology licensing collaborations with Pfizer, has further enhanced revenue [1].